GlaxoSmithKline plc (NYSE:GSK) Given Average Recommendation of “Hold” by Brokerages

Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK) has been given a consensus recommendation of “Hold” by the twenty-one research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $43.00.

A number of equities analysts have recently commented on GSK shares. Zacks Investment Research raised shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Morgan Stanley started coverage on shares of in a research report on Monday, June 17th. They set an “equal weight” rating and a GBX 215 ($2.81) target price on the stock.

NYSE GSK traded down $0.51 during trading on Tuesday, hitting $40.42. The stock had a trading volume of 4,313,971 shares, compared to its average volume of 2,128,528. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. The stock has a market cap of $100.27 billion, a PE ratio of 12.79, a price-to-earnings-growth ratio of 2.10 and a beta of 0.74. GlaxoSmithKline has a one year low of $36.41 and a one year high of $42.32. The firm’s 50 day moving average price is $40.07.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.13. The business had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 157.04%. On average, sell-side analysts expect that GlaxoSmithKline will post 2.91 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Stockholders of record on Friday, May 17th were given a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.90%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 58.86%.

In related news, Director Plc Glaxosmithkline bought 385,714 shares of GlaxoSmithKline stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $14.00 per share, with a total value of $5,399,996.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have bought 1,044,047 shares of company stock worth $16,249,991. Corporate insiders own 10.00% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Nachman Norwood & Parrott Inc purchased a new position in GlaxoSmithKline during the first quarter valued at approximately $201,000. Sphera Funds Management LTD. increased its holdings in GlaxoSmithKline by 38.7% during the first quarter. Sphera Funds Management LTD. now owns 430,000 shares of the pharmaceutical company’s stock valued at $17,970,000 after buying an additional 120,000 shares during the period. Wrapmanager Inc. increased its holdings in GlaxoSmithKline by 13.7% during the first quarter. Wrapmanager Inc. now owns 36,845 shares of the pharmaceutical company’s stock valued at $1,540,000 after buying an additional 4,434 shares during the period. PagnatoKarp Partners LLC increased its holdings in GlaxoSmithKline by 5.9% during the first quarter. PagnatoKarp Partners LLC now owns 7,384 shares of the pharmaceutical company’s stock valued at $313,000 after buying an additional 411 shares during the period. Finally, Pathlight Investors LLC purchased a new position in GlaxoSmithKline during the fourth quarter valued at approximately $675,000. 11.26% of the stock is currently owned by institutional investors.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What is a capital gain?

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ChannelAdvisor  Downgraded by Zacks Investment Research
ChannelAdvisor Downgraded by Zacks Investment Research
$0.29 EPS Expected for F.N.B. Corp  This Quarter
$0.29 EPS Expected for F.N.B. Corp This Quarter
VOLVO AB/ADR  Receives $17.00 Consensus Price Target from Analysts
VOLVO AB/ADR Receives $17.00 Consensus Price Target from Analysts
LatiumX  Market Cap Achieves $338,307.00
LatiumX Market Cap Achieves $338,307.00
Brokerages Set B2Gold Corp.  Target Price at C$5.43
Brokerages Set B2Gold Corp. Target Price at C$5.43
GoPower Hits 1-Day Trading Volume of $4,179.00
GoPower Hits 1-Day Trading Volume of $4,179.00


 
© 2006-2019 Zolmax.